ABBV-901 / AbbVie - LARVOL DELTA

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer (clinicaltrials.gov) - P1 | N=285 | Recruiting | Sponsor: AbbVie | N=219 ➔ 285

Adverse events • Enrollment change • First-in-human • Monotherapy • Platinum resistant • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC) (ESMO-Gynae 2026) - P1 | "Background The use of the antibody-drug conjugate (ADC) mirvetuximab soravtansine to target folate receptor alpha (FRα) and deliver a cytotoxic maytansine payload is a clinically validated strategy for patients with PROC and high expression levels of FRα. The primary endpoints are the rate of complete/partial response and the frequency and severity of adverse events. Key secondary endpoints include duration of response, progression free survival, and overall survival."

Clinical • Combination therapy • First-in-human • Monotherapy • P1 data • PK/PD data • Platinum resistant • Fallopian Tube Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1 • PROC